First project awards issued under Biopharmaceutical Manufacturing Preparedness-Consortium

The Biopharmaceutical Manufacturing Preparedness-Consortium (BioMaP-Consortium) is proud to announce inaugural awards to support the use of advanced biomanufacturing processes in domestic production of key starting materials and active pharmaceutical ingredients for essential medicines. The projects are funded by the Industrial Base Manufacturing and Supply Chain Office (IBMSC) of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services and leverage the Other Transaction Agreement with ASPR’s Biomedical Advanced Research and Development Authority (BARDA). These awards come eight months after the formation of BioMaP-Consortium in September 2023.

Antheia, Inc. received $11 million in federal funding for a two-year agreement to execute their project, “A Next-Generation Biomanufacturing Platform for Resilient, Agile, and Domestic Production of Critical Drug Substances” and Capra Biosciences, Inc. received $7.5 million for a two-year agreement to execute their project, “CoMPASS: Continuous BioManufacturing Process Analysis for Scaling API Synthesis.”

“These awards aim to enhance our nation’s capability within the biopharmaceutical manufacturing ecosystem, and we are excited to support the domestic production of biologically derived essential pharmaceutical ingredients,” said Mike Stebbins Ph.D., Sr. VP for ATI and lead for the Medical & Threat Countermeasures Division. “By harnessing the expertise of industry partners like Antheia, Inc. and Capra Biosciences, Inc., the BioMaP-Consortium is poised to make significant strides in addressing critical public health challenges through domestic production.”

Both projects are in support of IBMSC using the BioMaP-Consortium as a vehicle for the “Production of Biologically Derived Small Molecule Regulatory Staring Materials and/or Active Pharmaceutical Ingredients at Commercial Scale” solicitation and have been funded in whole or in part with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response (ASPR); Office of Industrial Base Manufacturing and Supply Chain (IBMSC), under OT number #75A50123D00003.

About the BioMaP-Consortium Partnership Vehicle

The BioMaP-Consortium is a new, 10-year, multi-purpose acquisition vehicle comprised of industry partners across the drug and vaccine manufacturing supply chain, including, but not limited to, drug substance manufacturers of required raw materials and consumables, suppliers of fill-finish services, and developers of innovative manufacturing technologies. This vehicle will help expand the industrial and manufacturing base for medical countermeasures during crises and inter-crises, to include the requisite capabilities, flexibilities, and strategies to secure needed medical supplies to meet the nation’s public health preparedness and response requirements. The BioMaP-Consortium is managed by Advanced Technology International.

For more information about the program and upcoming opportunities, please visit biomap-consortium.org.

The views expressed in this news release are those of ATI and may not reflect the official policy or position of the Department of Health and Human Services, Administration for Strategic Preparedness and Response or BARDA.